Improvements in colorectal cancer screening programmes - quantitative immunochemical faecal occult blood testing - how to set the cut-off for a particular population

Biomedical Papers

Volumn 156, Issue 2, 2012, Pages 143-150

  Kovarova, Jaroslava Tereza ^a   Zavoral, Miroslav ^a   Zima, Tomas ^a   Zak, Ales ^a   Kocna, Petr ^a   Kohout, Pavel ^b   Granatova, Jana ^b   Vanickova, Zdislava ^a   Vranova, Jana ^a   Suchanek, Stepan ^a   Benes, Zdenek ^b   Celko, Martin Alexander ^a   Povysil, Ctibor ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Thomayer Teaching Hospital Prague   (Czech Republic)

Author keywords

Colorectal cancer; Cut off; Czech Republic; Quantitative immunochemical test; Screening

Indexed keywords

ARTICLE; COLORECTAL TUMOR; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOLOGICAL PROCEDURES; MALE; MIDDLE AGED; OCCULT BLOOD; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOLOGIC TESTS; MALE; MIDDLE AGED; OCCULT BLOOD; ROC CURVE; SENSITIVITY AND SPECIFICITY;

NUCLEOPOLYHEDROVIRUS;

EID: 84864010699     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.030     Document Type: Article

References (30)

1. Zavoral M. Colorectal cancer screening in the Czech Republic. Z Gastroenterol 2008;46(Suppl 1):29-30.
2. Zavoral M, Suchanek S, Zavada F, Dusek L, Muzik J, Seifert B, Fric P. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15:5907-915.
3. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365-71.
4. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-77.
5. Crotta S, Castiglione G, Grazzini G, Valle F, Mosconi S, Rosset R. Feasibility study of colorectal cancer screening by immunochemical faecal occult blood testing: results in a nothern Italian community. Eur J Gastroenterol Hepatol 2004;16:33-7.
6. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150:162-9.
7. Young GP, Cole S. New stool screening tests for colorectal cancer. Digestion 2007;76:26-33.
8. Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008;17:1623-30.
9. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55.
10. Vogt W. Prevention of colorectal cancer-update 2008. Praxis 2008;97:1077-83.
11. Van Rossum LG, Van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E. Random comparison of guajac and immunochemical fecal occult blood test for colorectal cancer in screening population. Gastroenterology 2008;135:82-90.
12. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, van der Togt AC, Habbema JD, Kuipers EJ. Screening for colorectal cancer randomised trial comparing guaiacbased and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 201059:62-8.
13. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Lieberman N, Klang S, Niv Y. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low dose Aspirin, NSAIDS, and anticoagulants. Am J Gastroenterol 2009;104:933-8.
14. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
15. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastroinest Endosc Clin N Am 2002;12:1-9.
16. Brown LF, Fraser CG. Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. Ann Clin Biochem 2008;45:604-5.
17. Hanley JA, McNeil BJ. A Method of Comparing the Areas under the Receiver Operating Curves Derived from the Same Cases. Radiology 1983;148:839-43.
18. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer 2001;37:398-401.
19. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Jansen JB, Verbeek AL, Dekker E. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009;101:1274-81.
20. Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, Niv Y. Performance characreristics and evaluation of an automateddeveloped and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005;100:2519-25.
21. Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Leshno M, Niv Y. Identification of colorectal adenomas by a quantitative immunochemical fecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009;29:906-17.
22. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, Bortoli A, Castiglione G, Cazzola L, Confortini M, Mantellini P, Rubeca T, Zappa M. Immunochemical fecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009;100:259-65.
23. Deutekom M, van Rossum LG, van Rijn AF, Laheij RJ, Fockens P, Bossuyt PM, Dekker E, Jansen JB. Comparison of guaiac and immunological fecal occult bloos tests in colorectal cancer screening: the patient perspective. Scand J Gastroenterol. 2010;45:1345-9.
24. Park DI, Ryu S, Kim YH, Lee CK, Eun CS, Han DS. Comparison of Guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-25.
25. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther 2006;23:1359-64.
26. Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol 2006;7:127-31.
27. Hol L, Wilschut JA, Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, van der Togt AC, Kuipers EJ, Habbema JD, van Leerdam ME. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-10.
28. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, Launoy G. Comparison of a guaiac and immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009;100:1230-35.
29. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arséne D, Boutreux S, Tichet J, Launoy G. Comparison of a guaiac based and immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56:210-4.
30. Wilkins T, Reynolds PL. Colorectal cancer: a summary of the evidence for screening and prevention. Am Fam Physician 2008;78:1385-92.